All posts by GTCbio


Treating Diabetes in 2020: Beyond Insulin, What?

GTCbio | March 23rd, 2017

Diabetes is a condition that results from lack of insulin or lack of appropriate response to insulin causing abnormally high levels of glucose in the blood. Therefore, insulin supplementation provides significant benefit to diabetes patients. However, insulin does not address the root cause of the disease and therefore does not cure diabetes. There has been…read more

Responding to Emerging Infectious Diseases on the Global Stage

GTCbio | March 13th, 2017

In recent years, a handful of both naturally occurring and human-driven infectious disease threats and public health emergencies have surfaced. However, managing these infectious disease outbreaks effectively and efficiently have made it difficult for responders due to the unpredictable nature of these diseases. Nationally and globally led efforts are directed towards rapid response to such…read more

Overcoming challenges of clinical validation and translation of Biomarkers

GTCbio | March 6th, 2017

Various types of biomarkers are being developed to help with decision-making in drug-development and clinical practice. However, several challenges remain in understanding the clinical and economic drivers of biomarkers.  According to National Biomarker Development Alliance, the key requirement for biomarker validation is that it has to serve as a surrogate endpoint in a clinical trial….read more

How conferences can be transformational platforms?

Satish Medicetty | March 2nd, 2017

A month ago I shared my initial thoughts on how gtcbio is promoting a “Drive Together” concept to change conferences to transformational platforms. The image below will provide a high-level overview of our approach.  All our platforms will be built on key central pillars: content, stakeholders, relationships and connectivity.  Each individual pillar will have its…read more